HIPRA
Avda. la Selva. 135, 17170 Amer (Girona), Spain
Tel.: (34) 972 43 06 60 · hipra@hipra.com · www.hipra.com

HIPRA Appoints Meritxell Ferraté as Chief People & Organization Officer

Ferraté joins the company with the aim of continuing to develop the talent of HIPRA's nearly 3,000 professionals worldwide and supporting the company's international growth

Girona, 2 November, 2026 – HIPRA, a biotechnology pharmaceutical company specialising in the development of vaccines and biological products, has appointed **Meritxell Ferraté as Chief People & Organization Officer**. Ferraté **will lead the people management strategy for the company's nearly 3,000 professionals worldwide, across its 40 subsidiaries**, with the aim of fostering talent development, strengthening leadership and continuing to place people at the heart of HIPRA's strategy. She will also contribute to building a strong organisational structure that supports the company's international growth, in line with the values that define HIPRA: excellence, nonconformity and optimism.

With this appointment, HIPRA reaffirms its belief that a company's growth depends not only on innovation and technological capabilities, but also on the people who make it possible. This commitment is reflected in the strengthening of its leadership team and its determination to continue building an organisation ready to face future challenges.

A career focused on transformation and people development

Meritxell Ferraté brings more than 20 years of experience in people management, organisational transformation and talent development in international environments. Throughout her career, she has held senior leadership positions in the pharmaceutical industry, combining a strategic business perspective with a strong people-focused approach.

Most recently, she served as Chief Transformation Officer at Towa International. She holds a degree in Chemistry from the University of Barcelona, a degree in Industrial Technical Engineering from the Polytechnic University of Catalonia, and has completed the General Management Programme (PDG) at IESE Business School.

AboutHIPRA

HIPRA is a biotechnology pharmaceutical company focused on prevention in animal and human health (One Health), offering a wide range of highly innovative vaccines and advanced diagnostic services. With

its slogan **"Building immunity for a healthier world"**, HIPRA reaffirms its commitment to providing solutions that improve global health. The company has a strong international presence, with **40 subsidiaries, 3 R&D centres and 6 production centres** strategically located in Europe (Spain) and the Americas (Brazil). In addition, its extensive international distribution network enables the company to market its products in nearly 100 additional countries, covering all five continents.

Research and development are at the core of its expertise. HIPRA invests **approximately 15% of its annual turnover in R&D activities** and infrastructure focused on developing and applying the latest scientific advances to create innovative, high-quality vaccines. HIPRA has a portfolio of vaccines based on different technological platforms. Its R&D teams work with a wide range of technologies and biological modalities. To complement its expertise in vaccination, the company also develops medical devices and traceability services for animal health.

Press Contacts

Ivette Ballesteros – press@hipra.com – 972 430 660

Irene Calle – icalle@harmon.es – M. 609 873 052

José María Nieto – jnieto@harmon.es – M. 689 186 062